At Centauri we seek to tackle life-threatening infectious diseases in the most vulnerable patients.

Learn more
Alphamers

Our science

Centauri Therapeutics is an immunotherapy company focused on infectious diseases. All projects harness a powerful and clinically validated immune mechanism which redirects naturally existing antibodies to treat life-threatening diseases. Centauri holds an exclusive worldwide license to exploit the Alphamer® immunotherapeutics platform within the field of infectious disea

7.0m

immunocompromised people in the United States 1

60%

of haematological cancer deaths are infection related 2

$4.6bn

health care costs in the US to treat six antibiotic resistance threats 3

67,000

deaths annually in Europe and US due to drug-resistant bacterial infections 4 5

Bacteria

Latest News and Articles

Centauri welcomes Dr Rinki Deb

October 2, 2022

Centauri is delighted to welcome Dr Rinki Deb to the…

Read More

Centauri welcomes Dr Hassan Al-Bewani

July 18, 2022

Centauri welcomes Dr Hassan Al-Bewani who joins the scientific team…

Read More

Centauri strengthens senior leadership team with three key appointments

July 12, 2022

Centauri is pleased to announce that Jennifer Schneider, Helen Bright…

Read More

Citations

1. https://www.ama-assn.org/delivering-care/public-health/what-tell-immunocompromised-patients-about-covid-19-vaccines

2. Zembower, T.R. (2014). Epidemiology of Infections in Cancer Patients. In: Stosor, V., Zembower, T. (eds) Infectious Complications in Cancer Patients. Cancer Treatment and Research, vol 161. Springer, Cham https://doi.org/10.1007/978-3-319-04220-6_2

3. https://www.cdc.gov/drugresistance/solutions-initiative/stories/partnership-estimates-healthcare-cost.html

4. https://www.euro.who.int/en/health-topics/disease-prevention/pages/news/news/2022/01/whoecdc-report-antimicrobial-resistance-remains-threat-to-health-in-european-region

5. https://www.cdc.gov/media/releases/2019/p1113-antibiotic-resistant.html